These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1831937)

  • 1. Complement fragment C4d and Bb levels in inflammatory skin diseases (e.g. SLE, atopic dermatitis, erythroderma and pustulosis palmaris et plantaris) for assessment of complement activation.
    Takematsu H; Tagami H
    Tohoku J Exp Med; 1991 Apr; 163(4):263-8. PubMed ID: 1831937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the alternative pathway of complement in psoriatic lesional skin.
    Takematsu H; Tagami H
    Dermatologica; 1990; 181(4):289-92. PubMed ID: 2073958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity.
    Manzi S; Rairie JE; Carpenter AB; Kelly RH; Jagarlapudi SP; Sereika SM; Medsger TA; Ramsey-Goldman R
    Arthritis Rheum; 1996 Jul; 39(7):1178-88. PubMed ID: 8670328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy.
    Buyon JP; Tamerius J; Ordorica S; Young B; Abramson SB
    Arthritis Rheum; 1992 Jan; 35(1):55-61. PubMed ID: 1731815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preferential activation of the alternative pathway of complement in psoriatic lesional skin.
    Takematsu H; Tagami H
    Dermatology; 1992; 184(2):159-60. PubMed ID: 1498383
    [No Abstract]   [Full Text] [Related]  

  • 6. Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Comparison of the use of complement split products and conventional measurements of complement.
    Buyon JP; Tamerius J; Belmont HM; Abramson SB
    Arthritis Rheum; 1992 Sep; 35(9):1028-37. PubMed ID: 1418018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement activation in patients with systemic lupus erythematosus without nephritis.
    Mollnes TE; Haga HJ; Brun JG; Nielsen EW; Sjöholm A; Sturfeldt G; Mårtensson U; Bergh K; Rekvig OP
    Rheumatology (Oxford); 1999 Oct; 38(10):933-40. PubMed ID: 10534542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the activation pathways of the complement in psoriatic patients by use of complement fragment C4d and Bb measurements.
    Takematsu H; Tagami H
    Dermatologica; 1989; 179 Suppl 1():16-9. PubMed ID: 2789155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement activation during painful crisis in sickle cell anemia.
    Mold C; Tamerius JD; Phillips G
    Clin Immunol Immunopathol; 1995 Sep; 76(3 Pt 1):314-20. PubMed ID: 7554454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of the activation of the fourth component of complement (C4) with disease activity in systemic lupus erythematosus.
    Senaldi G; Makinde VA; Vergani D; Isenberg DA
    Ann Rheum Dis; 1988 Nov; 47(11):913-7. PubMed ID: 3264693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synovial fluid levels of complement SC5b-9 and fragment Bb are elevated in patients with rheumatoid arthritis.
    Brodeur JP; Ruddy S; Schwartz LB; Moxley G
    Arthritis Rheum; 1991 Dec; 34(12):1531-7. PubMed ID: 1747138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated levels of iC3b and C4d, but not Bb, complement fragments from plasma of persons infected with human T cell leukemia virus (HTLV) with HTLV-I-associated myelopathy/tropical spastic paraparesis.
    Saarloos MN; Koenig RE; Spear GT
    J Infect Dis; 1995 Oct; 172(4):1095-7. PubMed ID: 7561187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of detection of complement activation products in evaluating SLE activity.
    Nagy G; Brózik M; Varga L; Füst G; Kirschfink M; Kiss E; Gergely P
    Lupus; 2000; 9(1):19-25. PubMed ID: 10713643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ba and Bb fragments of factor B activation: fragment production, biological activities, neoepitope expression and quantitation in clinical samples.
    Kolb WP; Morrow PR; Tamerius JD
    Complement Inflamm; 1989; 6(3):175-204. PubMed ID: 2472921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement activation in severe Plasmodium falciparum malaria.
    Wenisch C; Spitzauer S; Florris-Linau K; Rumpold H; Vannaphan S; Parschalk B; Graninger W; Looareesuwan S
    Clin Immunol Immunopathol; 1997 Nov; 85(2):166-71. PubMed ID: 9344699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of C4 null alleles on C4 activation in systemic lupus erythematosus.
    Briggs DC; Senaldi G; Isenberg DA; Welsh KI; Vergani D
    Ann Rheum Dis; 1991 Apr; 50(4):251-4. PubMed ID: 2029208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Classical complement activation induced by pregnancy: implications for management of connective tissue diseases.
    Hopkinson ND; Powell RJ
    J Clin Pathol; 1992 Jan; 45(1):66-7. PubMed ID: 1740520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of the membrane attack complex during haemodialysis: impact of classical and alternative pathway components.
    Hauser AC; Derfler K; Stockenhuber F; Janata O; Balcke P
    Clin Sci (Lond); 1990 Nov; 79(5):471-6. PubMed ID: 2174314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative pathway of complement is activated during in vitro ventricular assist.
    Chen JC; Huynh TN; Serna DL; Sun CP; Ha H; Steward E; Webster S; Brenner M
    J Investig Med; 1999 Nov; 47(9):502-6. PubMed ID: 10572381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations in C3, C4, factor B, and related metabolites in septic shock.
    Lin RY; Astiz ME; Saxon JC; Saha DC; Rackow EC
    Clin Immunol Immunopathol; 1993 Nov; 69(2):136-42. PubMed ID: 8403550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.